Healthcare Closing with Large Advances; Novartis Tapped to Commercialize Anti-Fungal Treatment for EU Markets

By Staff,

Shutterstock photo

Top Healthcare Stocks

JNJ +1.81%

PFE +1.64%

ABT +3.97%

MRK +1.73%

AMGN +1.18%

Healthcare stocks have turned much higher with the NYSE Healthcare Sector Index gaining 1.5% and shares of healthcare companies in the S&P 500 adding 2.2% as a group.

In company news, Novartis AG ( NVS ) is up 1% at $77.48 a share in late afternoon trading and the drug-maker saying its Sandoz AG generics subsidiary has signed a collaboration agreement with Taiwan Liposome to commercialize its Liposomal Amphotericin B product in the eurozone and U.S. territories.

Amphotericin B is an anti-fungal often used intravenously to treat systemic fungal infections.

In other sector news,

(+) BCRX, Selects two plasma kallikrein inhibitors to advance into preclinical development as potential medications to prevent hereditary angioedema - a rapid swelling of the tissue just below the surface of the skin.

(-) OPXA, Prices offering of 4.12 mln shares at $1.70 apiece, generating about $7 mln in gross proceeds to support continued clinical studies of the company's Tcelna drug candidate in patients with secondary progressive multiple sclerosis.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing Commodities
Referenced Stocks: NVS

More from MT Newswires


MT Newswires

MT Newswires

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by